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How do these 3 diabetes agents 
compare in reducing mortality? 
A meta-analysis reveals that there may be advantages 
associated with SGLT-2 inhibitors and GLP-1 agonists 
that are not associated with DPP-4 inhibitors.
PRACTICE CHANGER 
Consider adding a sodium-glucose cotrans-
porter 2  (SGLT-2) inhibitor or a glucagon-like 
peptide 1 (GLP-1) agonist to the treatment 
regimen of patients with poorly controlled 
type 2 diabetes—especially those with higher 
CV risk. Doing so can reduce all-cause and 
cardiovascular (CV) mortality 1 
STRENGTH OF RECOMMENDATION
B: Based on a network meta-analysis of 236 
randomized controlled trials.
Zheng S, Roddick A, Aghar-Jaffar R, et al. Association between use of 
sodium-glucose cotransporter 2 inhibitors, glucagon-like peptide 1 
agonists, and dipeptidyl peptidase 4 inhibitors with all-cause mortality 
in patients with type 2 diabetes: a systematic review and meta-analysis. 
JAMA. 2018;319:1580-1591. 
ILLUSTRATIVE CASE 
A 64-year-old man with type 2 diabetes mel-
litus (T2DM) presents for a follow-up visit. 
His point-of-care hemoglobin A1c is 9.5%, 
and he is currently taking only metformin 
1000 mg bid. You are considering adding an 
SGLT-2 inhibitor, a GLP-1 agonist, or a dipeptidyl 
peptidase 4 (DPP-4) inhibitor to his treatment 
regimen. Which do you choose to better con-
trol his diabetes and reduce his all-cause and 
cardiovascular (CV) mortality risk?
Over the past several years, the num-ber of patients with T2DM has con-tinued to climb. In the United States, 
approximately 30 million people, or 1 of every 
11, now struggles to reduce their blood sugar.2 
As prevalence of the disease has increased, 
so has the number of medications available 
that are aimed at lowering blood sugar and 
improving diabetes control.2 In particular, 
the introduction of SGLT-2 inhibitors, GLP-1 
agonists, and DPP-4 inhibitors over the past 
several years has produced an area of some 
clinical ambiguity, due to the lack of random-
ized controlled trials (RCTs) comparing their 
efficacy. 
The “American Diabetes Association 
Standards of Medical Care in Diabetes” points 
specifically to the potential roles of the SGLT-2 
inhibitors empagliflozin and canagliflozin, 
and the GLP-1 agonist liraglutide, as agents 
that should be added to metformin and life-
style modification in patients with estab-
lished atherosclerotic CV disease. They cite 
data indicating that these drugs reduce major 
adverse CV events and CV mortality in this 
population.3 Deciding among these 3 medica-
tions, however, is left to providers and patients. 
For dual therapy in patients with T2DM without 
CV disease who remain hyperglycemic despite 
metformin and lifestyle modifications, SGLT-2 
inhibitors, GLP-1 agonists, and DPP-4 inhibi-
tors are recommended equally, with the choice 
among them to be determined by “consideration 
of drug-specific effects and patient factors.”3 
The National Institute for Health 
and Care Excellence (NICE) guidelines 
on T2DM management list both SGLT-2 
inhibitors and DPP-4 inhibitors among the 
potential options for intensifying therapy af-
ter metformin.4 The American Association of 
Clinical Endocrinologists and the American 
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College of Endocrinology guidelines do in-
clude a hierarchical recommendation to try 
a GLP-1 agonist first, followed by an SGLT-2 
inhibitor, followed by a DPP-4 inhibitor, after 
metformin and lifestyle modifications— 
although the difference in strength of recom-
mendations for these classes is noted to be 
small.5
STUDY SUMMARY
SGLT-2s, GLP-1s are associated with 
better mortality outcomes than DPP-4s
Zheng and colleagues performed a network 
meta-analysis of 236 RCTs involving 176,310 
patients to compare the clinical efficacy of 
SGLT-2 inhibitors, GLP-1 agonists, and DPP-4 
inhibitors to reduce all-cause mortality and 
CV endpoints in patients with T2DM. The 
authors analyzed English-language RCTs 
that followed patients with T2DM for at least 
12 weeks and compared SGLT-2 inhibitors, 
GLP-1 agonists, and DPP-4 inhibitors to one 
another, to placebo, or to no treatment. 
A majority of the patients in both the 
intervention and control groups were tak-
ing additional diabetes medications, such as 
metformin, prior to enrollment and during 
the trials. About half of the patients analyzed 
were enrolled in trials that specifically evalu-
ated patients at elevated CV risk, which is 
notable because patients with higher CV risk 
ultimately derived the most benefit from the 
treatments studied. 
The primary outcome was all-cause mor-
tality. Secondary outcomes were CV mortality, 
heart failure (HF) events, myocardial infarc-
tion (MI), unstable angina, and stroke, as well 
as the safety outcomes of hypoglycemia and 
adverse events (any events, serious events, 
and those leading to study withdrawal). 
❚ Results. Compared with the patients 
in the control groups (placebo or no treat-
ment), patients in both the SGLT-2 inhibitor 
and GLP-1 agonist groups had decreased 
all-cause mortality (SGLT-2 inhibitor group, 
hazard ratio [HR]=0.80; 95% credible interval 
[CrI], 0.71-0.89; absolute risk difference [RD]= 
–1%; number needed to treat [NNT]=100; 
GLP-1 agonist group, HR=0.88; 95% CrI, 0.81-
0.94; absolute RD= -0.6%; NNT=167). Patients 
in the DPP-4 inhibitor group did not have a 
difference in mortality compared with the 
control groups (HR=1.02; 95% CrI, 0.94-1.11; 
absolute RD=0.1%). Both the SGLT-2 inhibi-
tor (HR=0.78; 95% CrI, 0.68-0.90; absolute 
RD= –0.9%; NNT=111) and GLP-1 agonist 
(HR=0.86; 95% CrI, 0.77-0.96; absolute RD= 
–0.5%; NNT=200) groups had reduced all-
cause mortality when compared with the 
DPP-4 inhibitor group. 
❚ CV endpoints. Similarly, the SGLT-2 
inhibitor (HR=0.79; 95% Crl, 0.69-0.91; ab-
solute RD= –0.8%; NNT=125) and GLP-1 
agonist (HR=0.85; Crl, 95% 0.77-0.94; ab-
solute RD= –0.5%; NNT=200) groups had a 
reduction in CV mortality compared with 
the control groups, while those in the DPP-4 
inhibitor group experienced no effect. Addi-
tionally, those taking SGLT-2 inhibitors had 
lower rates of HF events (HR=0.62; 95% CrI, 
0.54-0.72; absolute RD= –1.1%; NNT=91) and 
MIs (HR=0.86; 95% CrI, 0.77–0.97; absolute 
RD= –0.6%; NNT=167) than those in the con-
trol groups. They also had lower rates of HF 
than those taking GLP-1 agonists (HR=0.67; 
95% CrI, 0.57 to 0.80; absolute RD= –0.9; 
NNT=111) or DPP-4 inhibitors (HR=0.55; 95% 
CrI, 0.46-0.67; absolute RD= –1.1%; NNT=91). 
Neither the GLP-1 agonist groups nor the 
DPP-4 inhibitor groups saw lower rates of HF 
or MI than the control groups. 
❚ Adverse effects. DPP-4 inhibitors, 
GLP-1 agonists, and SGLT-2 inhibitors were 
all associated with a small increased risk for 
hypoglycemia compared with the control 
groups, but there were no significant differ-
ences between drug classes. All agents re-
sulted in an increased risk for adverse events 
leading to trial withdrawal compared with 
the control groups (GPL-1 agonists, HR=2; 
95% CrI, 1.70-2.37; absolute RD=4.7%; num-
ber needed to harm [NNH]=21; SGLT-2 
inhibitors, HR=1.8; 95% CrI, 1.44-2.25; abso-
lute RD=5.8%; NNH=17; and DPP-4 inhibi-
tors, HR=1.93; 95% CrI, 1.59-2.35; absolute 
RD=3.1%; NNH=32). 
When compared with the control groups, 
the SGLT-2 inhibitor group was associated 
with an increased risk for genital infection 
(relative risk [RR]=4.19; 95% confidence 
interval [CI], 3.45-5.09; absolute RD=6%; 
NNH=16), but not of urinary tract infection or 
lower limb amputation, although the authors 
When compared 
to placebo or no 
treatment, the 
use of SGLT-2 
inhibitors or 
GLP-1 agonists 
is associated 
with lower all-
cause mortality 
and lower CV 
mortality than is 
the use of DPP-4 
inhibitors.
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noted high heterogeneity among studies 
with regard to the limb amputation out-
come. DPP-4 inhibitors were associated 
with an increased risk for acute pancre-
atitis (RR=1.58; 95% CI, 1.04-2.39; abso-
lute RD=0.1%; NNH=1000) compared with 
control groups.
WHAT’S NEW
SGLT-2s: Lower mortality, 
fewer heart failure events
This meta-analysis concludes that when com-
pared with placebo or no treatment, the use 
of SGLT-2 inhibitors or GLP-1 agonists is as-
sociated with lower all-cause mortality and 
lower CV mortality than is the use of DPP-4 
inhibitors. Additionally, SGLT-2 inhibitors are 
associated with lower rates of HF events than 
GLP-1 agonists or DPP-4 inhibitors.  
CAVEATS 
A lack of head-to-head RCTs
This study was a network meta-analysis 
that included many trials, the majority of 
which compared SGLT-1 inhibitors, GLP-1 
agonists, and DPP-4 inhibitors with con-
trols rather than to one another. Thus, the 
findings are not derived from a robust base 
of head-to-head RCTs involving the 3 classes 
of medication. 
However, there was relatively low het-
erogeneity among the studies included 
(I2=12), which lends strength to the meta-
analysis.6 Patients with the highest baseline 
CV risk likely gleaned the greatest benefits 
from these treatments and may have driv-
en much of the observed mortality reduc-
tion. This may limit the generalizability 
of the results to people with low CV risk. 
The comparative effectiveness and risk for 
adverse effects among individual medica-
tions within each class is unknown because 
the analysis was completed by drug class 
in order to adequately power the study to 
detect treatment effects.  
CHALLENGES TO IMPLEMENTATION 
Cost, adverse effects, and formulation  
may represent challenges
The cost of SGLT-2 inhibitors and 
GLP-1 agonists may present challenges to pa-
tients wishing to use these options. Addition-
ally, the increased risk for genital infections 
with SGLT-2 inhibitors, and of overall adverse 
effects (many of which were gastrointestinal) 
with GLP-1 agonists, must be considered. 
Lastly, the injectable formulation of GLP-1 
agonists may present a barrier to patients’ 
ability and willingness to effectively adminis-
ter these agents.                          JFP
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